Beta Bionics stock
BBNXNASDAQBeta Bionics, Inc., HealthcareISIN US08659B1026
46Score 46 out of 100, Weak
Price and trend
70 / 100
Price history
−41% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 42).
The price is 48% below its 52-week high. Largest decline in 2 years: 72% (January 2026 to April 2026).
Chart figures for advanced users
- SMA 50$18.54
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.81
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)42
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.86
- The lowest closing price of the last twelve months.
- Resistance$31.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Beta Bionics, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $742.78M, is number 68 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $100.25M (up 53.9% year on year) and a loss of $73.2M.
- For fiscal 2026, analysts expect on average revenue of $125.54M (up 25.2%) and adjusted earnings per share of −$2.04.
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 431 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 724.3% a year since 2022, Medical (Devices) median 13.8%.Growth 70
- More cash than debtCash $240.2M, financial debt $6.1M.Stability 69
- Share buybacksShare count down 5% since 2022.
Weaknesses
- Loss-makingLoss of $83.12M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 85% a year over the last 12 months.Stability 69
- Negative free cash flowFree cash flow −$65.96M over the last 12 months.Fundamentals 17
Its standout strengths are growth and technical analysis, while profitability and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 47 to 46.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 43.7% on the twelve months before. Revenue has grown strongly since 2022, at around 724% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 55%, operating −72%, net −73%. Last 12 months: net −65%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 16 Feb 2027in 95 days
- Last reported
- 27 Oct 2026EPS reported −$0.52 (expected −$0.52)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.04−1.4%
- Revenue
- $125.54M−0.9%
- Earnings per share
- −$2.13−2.1%
- Revenue
- $184.65M+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −13.0%Beta Bionics raised the low end of its 2026 revenue guidance to $124 million to $126 million, up from $121 million to $126 million, and now expects a smaller Mint-related revenue deferral of up to $8.5 million instead of $10 million in Q4, while reaffirming gross margin and pharmacy mix targets.
“We are increasing the lower end of our revenue guidance and now expect to generate total revenue of $124 million to $126 million, up from our prior guidance of $121 million to $126 million. The updated guidance reflects our expectation to generate $29 million to $31 million of revenue in the fourth quarter.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $3.22M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Feider StephenSale
9 Nov 2026, Chief Financial Officer
- Shares
- 744
- Price
- $17.00
- Value
- $12,649
- Feider StephenSale
5 Nov 2026, Chief Financial Officer
- Shares
- 382
- Price
- $17.04
- Value
- $6,508
- Hopman MarkSale
2 Nov 2026, Chief Commercial Officer
- Shares
- 370
- Price
- $16.90
- Value
- $6,253
Show 29 more
- Mensinger MikeSale
27 Oct 2026, Chief Product Officer
- Shares
- 2,650
- Price
- $22.00
- Value
- $58,300
- Hopman MarkSale
26 Oct 2026, Chief Commercial Officer
- Shares
- 821
- Price
- $20.00
- Value
- $16,420
- Hopman MarkSale
14 Oct 2026, Chief Commercial Officer
- Shares
- 775
- Price
- $17.35
- Value
- $13,446
- Hopman MarkSale
1 Oct 2026, Chief Commercial Officer
- Shares
- 370
- Price
- $18.96
- Value
- $7,015
- Jones ChristySale
22 Sept 2026, Board
- Shares
- 6,430
- Price
- $23.00
- Value
- $147,890
- Hopman MarkSale
16 Sept 2026, Chief Commercial Officer
- Shares
- 30,779
- Price
- $20.13
- Value
- $619,640
- Mensinger MikeSale
16 Sept 2026, Chief Product Officer
- Shares
- 2,650
- Price
- $22.00
- Value
- $58,300
- Hopman MarkSale
14 Sept 2026, Chief Commercial Officer
- Shares
- 775
- Price
- $15.52
- Value
- $12,028
- Hopman MarkSale
9 Sept 2026, Chief Commercial Officer
- Shares
- 35,994
- Price
- $18.46
- Value
- $664,550
- Saint SeanSale
3 Sept 2026, President & CEO
- Shares
- 5,641
- Price
- $20.08
- Value
- $113,259
- Hopman MarkSale
2 Sept 2026, Chief Commercial Officer
- Shares
- 5,327
- Price
- $19.11
- Value
- $101,815
- Russell Steven JonSale
2 Sept 2026, Chief Medical Officer
- Shares
- 4,221
- Price
- $19.11
- Value
- $80,676
- Mensinger MikeSale
2 Sept 2026, Chief Product Officer
- Shares
- 4,375
- Price
- $19.11
- Value
- $83,620
- Feider StephenSale
2 Sept 2026, Chief Financial Officer
- Shares
- 6,675
- Price
- $19.11
- Value
- $127,580
- Saint SeanSale
2 Sept 2026, President & CEO
- Shares
- 16,867
- Price
- $19.11
- Value
- $322,381
- Feider StephenSale
29 Jun 2026, Chief Financial Officer
- Shares
- 4,896
- Price
- $17.03
- Value
- $83,381
- Feider StephenSale
26 Jun 2026, Chief Financial Officer
- Shares
- 5,104
- Price
- $17.05
- Value
- $87,006
- Hopman MarkSale
24 Jun 2026, Chief Commercial Officer
- Shares
- 1,258
- Price
- $15.01
- Value
- $18,880
- Jones ChristySale
24 Jun 2026, Board
- Shares
- 1,406
- Price
- $15.00
- Value
- $21,090
- Hopman MarkSale
4 Jun 2026, Chief Commercial Officer
- Shares
- 275
- Price
- $12.31
- Value
- $3,385
- Jones ChristySale
4 Jun 2026, Board
- Shares
- 2,811
- Price
- $14.00
- Value
- $39,354
- Mensinger MikeSale
2 Jun 2026, Chief Product Officer
- Shares
- 4,378
- Price
- $12.61
- Value
- $55,194
- Hopman MarkSale
2 Jun 2026, Chief Commercial Officer
- Shares
- 5,329
- Price
- $12.61
- Value
- $67,183
- Russell Steven JonSale
2 Jun 2026, Chief Medical Officer
- Shares
- 4,222
- Price
- $12.61
- Value
- $53,227
- Feider StephenSale
2 Jun 2026, Chief Financial Officer
- Shares
- 6,676
- Price
- $12.61
- Value
- $84,165
- Saint SeanSale
2 Jun 2026, President & CEO
- Shares
- 16,872
- Price
- $12.61
- Value
- $212,707
- Lezack AdamSale
22 May 2026, Board
- Shares
- 998
- Price
- $11.21
- Value
- $11,188
- Jones ChristySale
21 May 2026, Board
- Shares
- 1,998
- Price
- $9.95
- Value
- $19,880
- Lezack AdamSale
21 May 2026, Board
- Shares
- 1,000
- Price
- $9.95
- Value
- $9,950
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Beta Bionics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Varex ImagingVREX $775.81M52
- InModeINMD $759.01M70
- Delcath SystemsDCTH $743.77M64
- BioventusBVS $743.63M60
- Cytek BiosciencesCTKB $721.93M46
- Synektik Spólka AkcyjnaSNT.WA $718.95M78
- Senseonics HoldingsSENS $659.99M44
- Xvivo PerfusionXVIVO.ST $640.54M50
ETFs that hold Beta Bionics
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.